A Single Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusion and Intravenous Bolus Administration of MK-2060 in Healthy Participants
Latest Information Update: 16 Jan 2025
At a glance
- Drugs MK 2060 (Primary)
- Indications Venous thrombosis
- Focus Adverse reactions
- Acronyms MK-2060-016
- Sponsors Merck Sharp & Dohme
- 13 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 18 Dec 2024 Planned End Date changed from 3 Jun 2025 to 24 Apr 2025.
- 18 Dec 2024 Planned primary completion date changed from 3 Jun 2025 to 24 Apr 2025.